Get caught up quickly on the top news and calls moving stocks with these Top Five lists.
1. STOCK NEWS:
- Gilead Sciences (GILD) and Jounce Therapeutics (JNCE) amended their existing license agreement for GS-1811, enabling Gilead to buyout remaining contingent payments potentially due under the license agreement for $67M [more]
- ExxonMobil (XOM) sues EU over new windfall tax on oil groups, FT reports [more]
- Amazon (AMZN) planning stand-alone sports app, The Information reports [more]
- Disney (DIS) says "Avatar: The Way of Water" tops $1B in global sales [more]
- Latin American digital grocer Merqueo files for IPO, seeks to list shares on Nasdaq under symbol "MERQ" [more]
2. WALL STREET CALLS:
- Generac (GNRC) was initiated with a Buy at Janney Montgomery Scott and named a top pick for 2023 at Northland [more]
- Baird cuts Tesla (TSLA) target to $252, keeps as "Best Idea" in 2023 [more]
- Akili (AKLI) initiated with an Equal Weight at Morgan Stanley [more]
- Ideaya Biosciences (IDYA) initiated with an Overweight at Capital One [more]
- Riot (RIOT), Rivian (RIVN) among Cantor's top technology picks for 2023 [more]
3. MOVERS:
- TG Therapeutics (TGTX) advanced after receiving FDA approval for Briumvi [more]
- Akoustis Technologies (AKTS) rose after the company said one of its filter designs will be incorporated in 5G mobile handsets and devices for an un-named "leading multibillion-dollar" customer [more]
- Kala Pharmaceuticals (KALA) surged after the FDA accepted an investigational new drug application for the company's lead product candidate, KPI-012, for the treatment of persistent corneal epithelial defect, or PCED [more]
- Tilray (TLRY) declines in New York after Piper Sandler reduced its sales estimates for the company [more]
- Meta Materials (MMAT) gains in New York after announcing it would demonstrate its technology collaborations at CES 2023 [more]
INDEXES:
The Dow fell 365.85, or 1.10%, to 32,875.71, the Nasdaq lost 139.94, or 1.35%, to 10,213.29, and the S&P 500 declined 46.03, or 1.20%, to 3,783.22.